The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study

This exploratory study tests a combination of three treatments — drug-loaded microsphere bronchial artery chemoembolization (a way to deliver chemotherapy directly into lung tumor blood vessels), anlotinib (an oral targeted drug), and adebelimumab (an immunotherapy) — as a third-line treatment for advanced non-small cell lung cancer (NSCLC). **You may be eligible if...** - You are 18 or older - You have been diagnosed with NSCLC (Stage III or IV) confirmed by biopsy - You have already tried two prior treatment regimens that did not work - You are in reasonable health (ECOG score of 2 or less) - Your life expectancy is more than 3 months **You may NOT be eligible if...** - You have not tried at least two prior treatments - You have serious bleeding problems or cannot undergo the bronchial artery procedure - You have active autoimmune disease or are on high-dose steroids - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.